Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Jul;13(7):945-50.
doi: 10.1046/j.1365-2036.1999.00512.x.

A non-toxic analogue of a coeliac-activating gliadin peptide: a basis for immunomodulation?

F Biagi  1 , H J Ellis, N D Parnell, R G Shidrawi, P D Thomas, N O'Reilly, G R Corazza, P J Ciclitira
Affiliations

A non-toxic analogue of a coeliac-activating gliadin peptide: a basis for immunomodulation?

F Biagi et al. Aliment Pharmacol Ther. 1999 Jul.

Abstract

Background: A-gliadin residues 31-49 (peptide A) binds to HLA-DQ2 and is toxic to coeliac small bowel. Analogues of this peptide, which bind to DQ2 molecules but are non-toxic, may be a potential route to inducing tolerance to gliadin in patients with coeliac disease.

Methods: Toxicity was investigated with small bowel organ culture in six patients with untreated coeliac disease, four with treated coeliac disease and six controls. Analogue peptides comprised alanine substituted variants of peptide A at L31 (peptide D), P36 (E), P38 (F), P39 (G) and P42 (H).

Results: Peptides D and E were toxic in biopsies from some patients. Peptides F, G and H were not toxic.

Conclusions: Peptide F, which binds to DQ2 more strongly than peptide A, is not toxic in patients with coeliac disease in-vitro; this could be an initial step towards investigation of the induction of tolerance to gliadin in patients affected by coeliac disease.

PubMed Disclaimer

Publication types

LinkOut - more resources